Differential Gene Expression in Ductal Carcinoma in Situ of the                     Breast Based on ERBB2 Status

Agosto‐Arroyo, Emmanuel; Isayeva, Tatyana; Wei, Shi; Almeida, Jonas S.; Harada, Shuko

doi:10.1177/107327481702400117

Cited by 7 publications

(3 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some recent studies pointed out the negative prognostic value of Her2 in both DCIS and DCISM. [47–49] Unfortunately, this data may be missing in cases of microinvasion if the focus does not provide enough material to be immunohistochemically tested. In fact, in our study, we could not find survival differences in DCIS or DCISM in respect to Her2 positivity, because it was available only in a limited number of cases.…”

Section: Discussionmentioning

confidence: 99%

Sentinel lymph node biopsy in patients affected by breast ductal carcinoma in situ with and without microinvasion

Bertozzi

Cedolini

Londero³

et al. 2019

Medicine

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Sentinel lymph node biopsy in patients affected by breast ductal carcinoma in situ with and without microinvasion

Bertozzi

Cedolini

Londero³

et al. 2019

Medicine

View full text Add to dashboard Cite

show abstract

“… 61 Agosto-Arroyo et al. 62 found that the overexpression of TAOK1 in the ERBB2 subtype could be associated with the occurrence of invasive breast cancer. Thean et al.…”

Section: Discussionmentioning

confidence: 99%

Comprehensive analysis to identify DLEU2L/TAOK1 axis as a prognostic biomarker in hepatocellular carcinoma

Shi

Zhang

Liu

et al. 2021

Molecular Therapy - Nucleic Acids

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the deadliest malignant tumors that are harmful to human health. Increasing evidence has underscored the critical role of the competitive endogenous RNA (ceRNA) regulatory networks among various human cancers. However, the complexity and behavior characteristics of the ceRNA network in HCC were still unclear. In this study, we aimed to clarify a phosphatase and tensin homolog (PTEN)-related ceRNA regulatory network and identify potential prognostic markers associated with HCC. The expression profiles of three RNAs (long non-coding RNAs [lncRNAs], microRNAs [miRNAs], and mRNAs) were extracted from The Cancer Genome Atlas (TCGA) database. The DLEU2L-hsa-miR-100-5p/ hsa-miR-99a-5p-TAOK1 ceRNA network related to the prognosis of HCC was obtained by performing bioinformatics analysis. Importantly, we identified the DLEU2L/TAOK1 axis in the ceRNA by using correlation analysis, and it appeared to become a clinical prognostic model by Cox regression analysis. Furthermore, methylation analyses suggested that the abnormal upregulation of the DLEU2L/TAOK1 axis likely resulted from hypomethylation, and immune infiltration analysis showed that the DLEU2L/TAOK1 axis may have an impact on the changes in the tumor immune microenvironment and the development of HCC. In summary, the current study constructing a ceRNA-based DLEU2L/TAOK1 axis might be a novel important prognostic factor associated with the diagnosis and prognosis of HCC.

show abstract

“…HER2 overexpression in human breast cancer indicates a risk of recurrence independent of whether the axillary node is positive or negative for micrometastases . Overexpression of HER2 is often observed (50%) in ductal carcinomas . A clear role for HER2 overexpression in the progression from ductal carcinoma in situ (DCIS) to invasive carcinoma has not been shown, although dimerization of epidermal growth factor receptor (EGFR) and HER2 induces motility …”

Section: Introductionmentioning

confidence: 99%

Dasatinib inhibition of cSRC prevents the migration and metastasis of canine mammary cancer cells with enhanced Wnt and HER signalling

Timmermans-Sprang

Mestemaker

Steenlage

et al. 2019

Vet Comparative Oncology

View full text Add to dashboard Cite

Human epidermal growth factor 2 (HER2) overexpression leads to aggressive mammary tumour growth. Although the prognosis of HER2+ tumours in humans is greatly improved using biologicals, therapy resistance, which may be caused by increased phosphatidyl‐3‐kinase (PI3K), rous sarcoma proto‐oncogene (cSRC) or wingless‐type MMTV integration site family (Wnt) activity, is a major concern. A recent analysis of 12 canine mammary cell lines showed an association between HER2/3 overexpression and phosphatase and tensin homologue (PTEN) deletion with elevated Wnt‐signalling. Wnt‐activity appeared to be insensitive to phosphatidyl‐3‐kinase (PI3K) inhibitors but sensitive to Src‐I1. We hypothesized that Wnt activation, was caused by HER2/3‐activated cSRC activation. The role of HER2/3 on Wnt signalling was investigated by silencing HER2/3 expression using specific small interfering RNA (siRNAs). Next, the effect of an epidermal growth factor receptor (EGFR)/HER2 tyrosine kinase inhibitor on Wnt activity and migration was investigated and compared to other tyrosine kinase inhibitors (TKIs) of related signalling pathways. Finally, two TKIs, a cSRC and a PI3K inhibitor, were investigated in a zebrafish xenograft model. Silencing of HER1‐3 did not inhibit the intrinsic high Wnt activity, whereas the HER kinase inhibitor afatinib showed enhanced Wnt activity. The strongest inhibition of Wnt activity and cell viability and migration was shown by cSRC inhibitors, which also showed strong inhibition of cell viability and metastasis in a zebrafish xenograft model. HER2/3 overexpression or HER2/3‐induced cSRC activation is not the cause of enhanced Wnt activity. However, inhibition of cSRC resulted in a strong inhibition of Wnt activity and cell migration and metastasis. Further studies are needed to unravel the mechanism of cSRC activation and cSRC inhibition to restore sensitivity to HER‐inhibitors in HER2/3‐positive breast cancer.

show abstract

Differential Gene Expression in Ductal Carcinoma in Situ of the Breast Based on ERBB2 Status

Abstract: Background: The molecular signature of ductal carcinoma in situ (DCIS)

Cited by 7 publications

References 71 publications

Sentinel lymph node biopsy in patients affected by breast ductal carcinoma in situ with and without microinvasion

Sentinel lymph node biopsy in patients affected by breast ductal carcinoma in situ with and without microinvasion

Comprehensive analysis to identify DLEU2L/TAOK1 axis as a prognostic biomarker in hepatocellular carcinoma

Dasatinib inhibition of cSRC prevents the migration and metastasis of canine mammary cancer cells with enhanced Wnt and HER signalling

Contact Info

Product

Resources

About